Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

All eyes are on Alnylam as the company awaits entry into the transthyretin amyloid cardiomyopathy market, which currently ...

Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for ...

The biotech is exploring opportunities for a reverse merger or other business combinations. CFO and now interim CEO Anup ...

The CDC budget cuts could pose headwinds for HIV drugmakers like Gilead and Merck but are unlikely to severely cripple their ...

Layoffs leave more than empty desks—they leave uncertainty, guilt and anxiety. Three simple steps will help you regain ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

The ongoing conflicts between Ukraine and Russia, as well as Israel and Palestine, have sent ripples across various ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Japan-based Taiho Pharmaceutical has worked with Araris Biotech since 2023 developing antibody-drug conjugates for the ...